TEJ-KOHLI-FOUNDATION
10.10.2019 08:02:07 CEST | Business Wire | Press release
On World Sight Day, the Tej Kohli Foundation says that a focus on new technologies is needed to accelerate the global mission to end curable corneal blindness worldwide. The Foundation is currently funding the clinical trials and development of a ‘liquid biosynthetic’ solution that could offer an accessible, scalable and affordable solution to corneal blindness that would be relevant to many of the 12 million people worldwide who suffer from this type of blindness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005535/en/
The thesis of the Tej Kohli Foundation is that humanitarian efforts the world over will be greatly advanced by exponential growth technologies such as AI, robotics and genomics. The Foundation behaves like a venture fund by backing, incubating, acquiring and accelerating the development of technology solutions. Only successful projects secure further funding support, leaving the Foundation agile to back the projects that will have the greatest impact.
Blindness is heavily impacted by poverty. According to the WHO, 14 million of the 39 million people who are blind live in India. 12.7 million people are currently waiting for a cornea transplant, including 6 million in India. The Tej Kohli Foundation’s ‘Cornea Institute’ at the LV Prasad Eye Institute in Hyderabad already conducts thousands of corneal transplants every year using donor cornea, largely for free. The Foundation recently cured five brothers and sisters in the same family from Rajasthan who had all been suffering with long-term visual impairment.
But the limited supply of donor cornea and the need for invasive surgery means that worldwide less than 1 in 70 will receive a cornea transplant each year. Artificial cornea or keratoprotheses are expensive and can cost up to US$20,000. The Tej Kohli Foundation is backing the development of technological solutions, because ending corneal blindness will require an affordable, accessible and scalable solution that does not rely on transplantation.
The Tej Kohli Foundation previously backed methods of synthesising artificial cornea from yeast and peptides, but new advances mean it has switched this funding to the development of the liquid biosynthetic, which aims to work by causing the regeneration of corneal tissue. The pro-regeneration tissue replacement could avoid the need for expensive corneal grafting and be applied in less than thirty minutes to fill a perforation or to repair a corneal ulcer.
In July 2018 the Tej Kohli Foundation also made a $2m gift to Massachusetts Ear and Eye, a teaching hospital of Harvard Medical School, to fund innovation in research into nano-string and DNA-sequencing technologies for early diagnostics and prevention, as well as ‘GelCORE,’ an adhesive biomaterial for replacing corneal tissue.
Michael Macfarlane, spokesperson for the Tej Kohli Foundation:
“There are limits to the number of corneal transplants that can take place each year, especially in poor and remote rural areas. The Tej Kohli Foundation is a global focal point for scientists and others who are developing pioneering treatments in this field. Our mission is to work with a range of partners in our goal to eliminate corneal blindness by 2035.”
Tej Kohli, co-Founder of the Tej Kohli Foundation:
“Eliminating corneal blindness is what I am most passionate about. I favour a venture-led approach to philanthropy whereby we bring people together and provide the funding to accelerate the development of solutions that might bring us a step closer to ending corneal blindness. The way that we run our Foundation is directly aligned with how we manage our commercial ventures and investments, and this approach means we can drive greater progress from every pound or dollar or rupee that we spend on achieving our mission.”
Find out more about the Tej Kohli Foundation at: http://www.tejkohlifoundation.com
A video about a family of five siblings having their long-term visual impairment cured by the Tej Kohli Foundation is available to embed using this link: https://youtu.be/Pmcb9pRxOSs
A video interview with Wendy and Tej Kohli in which they talk about the work of the Tej Kohli Foundation is available to embed using this link: https://youtu.be/JgOO4Cs-jnw
A video about the Tej Kohli Cornea Program is available to embed using this link: https://youtu.be/2zUBtj6H7GM
A video about the Tej Kohli Cornea Institute is available to embed using this link: https://youtu.be/lkZmI8lkpm8
About The Tej Kohli Foundation
The Tej Kohli Foundation was launched by Wendy and Tej Kohli in 2005 as a focal point for their global philanthropic endeavours. The Foundation includes:
- Cornea Institute: which since 2016 has seen more than 180,000 outpatients and carried out 17,000+ cornea replacement surgeries, largely for free.
- Cornea Program: which funds innovation in research to cure corneal blindness at Mass. Eye and Ear, a teaching hospital of Harvard Medical School.
- Applied Research: which is engaged in the acquisition and development of new technologies that have the potential to substantially reduce corneal blindness globally.
- Impact Initiatives: which supports projects in underserved communities where direct interventions can have a sustained and positive impact upon individual lives.
http://www.tejkohlifoundation.com
About Tej Kohli
Tej Kohli is a London-based investor and entrepreneur with a well-publicized mission to cure corneal blindness worldwide by 2035. He first rose to success during the dotcom boom selling technology solutions and e-commerce payments software before becoming a real estate investor in technology hubs. He now focuses on high-impact investments into AI, robotics, biotech and genomics ventures. Tej Kohli is a Distinguished Alumni of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering.
END
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005535/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
Grindr Nominates Three New Directors to Its Board of Directors30.4.2026 23:16:00 CEST | Press release
Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu
The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’30.4.2026 22:42:00 CEST | Press release
New Tickets, Exclusive Offers, and Special Anniversary Programs Kick off May 1 The Empire State Building (ESB), the “World’s Most Famous Building,” will celebrate its 95th anniversary on May 1, 2026, with new offers at the Empire State Building Observation Deck, a special birthday tower lighting display, and a slate of celebrations to honor its legacy and future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430693323/en/ The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’ “The Empire State Building celebrates its 95th anniversary, still the ‘World’s Most Famous Building,’ a modernized, sustainability leader as technologically advanced today as the day she was completed, and the winner of #1 Top Attraction in the United States in Tripadvisor’s Travelers’ Choice Awards for 2026,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. Anniversary Offerings and Experiences To
MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis30.4.2026 22:17:00 CEST | Press release
Recognizes the potential of MH002 to address a serious medical condition with high unmet need Enables accelerated development and increased FDA interactions to streamline review process MRM Health will be presenting at upcoming Digestive Disease Week (DDW) 2026, taking place from May 2nd – May 5th in Chicago, IL, USA MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC). MH002 today is the most advanced LBP targeting inflammatory bowel disease (IBD)-specific mechanisms and is composed of a rationally designed microbial consortium of six well-characterized commensal strains. The FDA’s Fast Track is a process d
Rimini Street Announces Fiscal First Quarter 2026 Financial and Operating Results30.4.2026 22:01:00 CEST | Press release
First Quarter Financial Highlights Include: Remaining Performance Obligations (RPO) of $643.6 million, up 16.4% year over year Adjusted Calculated Billings of $92.2 million, up 22.9% year over year Adjusted Annualized Recurring Revenue (ARR) of $388.0 million, up 5.0% year over year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal first quarter ended March 31, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430598629/en/ Rimini Street Announces Fiscal First Quarter 2026 Financial and Operating Results “Our first quarter results reflect continued growth and accelerating momentum in our core Rimini Support™ business as organizations turn to the proven Rimini Smart Path™ to execute their global E
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
